Early growth response protein 1 upregulation and nuclear translocation by 2'-benzoyloxycinnamaldehyde induces prostate cancer cell death

Cancer Letters

Volumn 329, Issue 2, 2013, Pages 217-227

  Kang, Hye Sook ^a   Ock, Jiyeon ^a   Lee, Heon Jin ^a   Lee, Yu Jin ^b   Kwon, Byoung Mog ^b   Hong, Su Hyung ^a  

^a Kyungpook National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

2' Benzoyloxycinnamaldehyde (BCA); Activating transcription factor 3 (ATF3); Early growth response protein 1 (EGR1); Growth arrest and DNA damage inducible protein alpha (GADD45A); Importin 7 (IPO7); NSAID activated gene 1 protein (NAG 1); Prostate cancer cells

Indexed keywords

2' BENZOYLOXYCINNAMALDEHYDE; ACTIVATING TRANSCRIPTION FACTOR 3; ANTINEOPLASTIC AGENT; EARLY GROWTH RESPONSE FACTOR 1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IMPORTIN 7; NSAID ACTIVATED GENE 1 PROTEIN; NUCLEAR PROTEIN; PLANT MEDICINAL PRODUCT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACTIVATING TRANSCRIPTION FACTOR 3 GENE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL VIABILITY; CINNAMOMUM CASSIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE TRANSLOCATION; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN ALPHA GENE; HUMAN; HUMAN CELL; MALE; NSAID ACTIVATED GENE 1; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION; UPREGULATION;

ACROLEIN; ACTIVATING TRANSCRIPTION FACTOR 3; ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZOATES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLUTATHIONE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; KARYOPHERINS; MALE; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84872486137     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.006     Document Type: Article

References (47)

1. Kwon B.M., Lee S.H., Cho Y.K., Bok S.H., So S.H., Youn M.R., Chang S.I. Synthesis and biological activity of cinnamaldehydes as anbiogenesis inhibitors. Bioorg. Med. Chem. Lett. 1997, 7:2473-2476.
2. Kwon B.M., Cho Y.K., Lee S.H., Nam J.Y., Bok S.H., Chun S.K., Kim J.A., Lee I.R. 2'-Hydroxycinnamaldehyde from stem bark of Cinnamomum cassia. Planta Med. 1996, 62:183-184.
3. Han D.C., Lee M.Y., Shin K.D., Jeon S.B., Kim J.M., Son K.H., Kim H.C., Kim H.M., Kwon B.M. 2'-Benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species. J. Biol. Chem. 2004, 279:6911-6920.
4. Hong S.H., Kim J., Kim J.M., Lee S.Y., Shin D.S., Son K.H., Han D.C., Sung Y.K., Kwon B.M. Apoptosis induction of 2'-hydroxycinnamaldehyde as a proteasome inhibitor is associated with ER stress and mitochondrial perturbation in cancer cells. Biochem. Pharmacol. 2007, 74:557-565.
5. Ock J., Lee H.A., Ismail I.A., Lee H.J., Kwon B.M., Suk K., Lee W.H., Hong S.H. Differential antiproliferation effect of 2'-benzoyloxycinnamaldehyde in K-ras-transformed cells via downregulation of thiol antioxidants. Cancer Sci. 2011, 102:212-218.
6. Hayat M.J., Howlader N., Reichman M.E., Edwards B.K. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program. Oncologist 2007, 12:20-37.
7. Zhang X., Liu Y. Suppression of HGF receptor gene expression by oxidative stress is mediated through the interplay between Sp1 and Egr-1. Am. J. Physiol. Renal Physiol. 2003, 284:F1216-1225.
8. Liu C., Rangnekar V.M., Adamson E., Mercola D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther. 1998, 5:3-28.
9. Sukhatme V.P., Cao X.M., Chang L.C., Tsai-Morris C.H., Stamenkovich D., Ferreira P.C., Cohen D.R., Edwards S.A., Shows T.B., Curran T., et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 1988, 53:37-43.
10. Liu C., Yao J., Mercola D., Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J. Biol. Chem. 2000, 275:20315-20323.
11. Huang R.P., Fan Y., de Belle I., Niemeyer C., Gottardis M.M., Mercola D., Adamson E.D. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int. J. Cancer 1997, 72:102-109.
12. Calogero A., Arcella A., De Gregorio G., Porcellini A., Mercola D., Liu C., Lombari V., Zani M., Giannini G., Gagliardi F.M., Caruso R., Gulino A., Frati L., Ragona G. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin. Cancer Res. 2001, 7:2788-2796.
13. Eid M.A., Kumar M.V., Iczkowski K.A., Bostwick D.G., Tindall D.J. Expression of early growth response genes in human prostate cancer. Cancer Res. 1998, 58:2461-2468.
14. Mora G.R., Olivier K.R., Cheville J.C., Mitchell R.F., Lingle W.L., Tindall D.J. The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate. Mol. Cancer Res. 2004, 2:115-128.
15. Zagurovskaya M., Shareef M.M., Das A., Reeves A., Gupta S., Sudol M., Bedford M.T., Prichard J., Mohiuddin M., Ahmed M.M. EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 2009, 28:1121-1131.
16. Chiu S.C., Wang M.J., Yang H.H., Chen S.P., Huang S.Y., Chen Y.L., Lin S.Z., Harn H.J., Pang C.Y. Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells. BMC. Cancer 2011, 11:146.
17. Chen J., Liu M.Y., Parish C.R., Chong B.H., Khachigian L. Nuclear import of early growth response-1 involves importin-7 and the novel nuclear localization signal serine-proline-serine. Int. J. Biochem. Cell Biol. 2011, 43:905-912.
18. Fan F., Jin S., Amundson S.A., Tong T., Fan W., Zhao H., Zhu X., Mazzacurati L., Li X., Petrik K.L., Fornace A.J., Rajasekaran B., Zhan Q. ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 2002, 21:7488-7496.
19. Mashima T., Udagawa S., Tsuruo T. Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis. J. Cell. Physiol. 2001, 188:352-358.
20. Stearns M.E., Kim G., Garcia F., Wang M. Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX-1532 Cells. Mol. Cancer Res. 2004, 2:403-416.
21. Bottone F.G., Moon Y., Kim J.S., Alston-Mills B., Ishibashi M., Eling T.E. The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol. Cancer Ther. 2005, 4:693-703.
22. Bottone F.G., Martinez J.M., Collins J.B., Afshari C.A., Eling T.E. Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis. J. Biol. Chem. 2003, 278:25790-25801.
23. Bottone F.G., Moon Y., Alston-Mills B., Eling T.E. Transcriptional regulation of activating transcription factor 3 involves the early growth response-1 gene. J. Pharmacol. Exp. Ther. 2005, 315:668-677.
24. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J., Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol. 2005, 67:356-364.
25. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 2001, 59:901-908.
26. Liu T., Bauskin A.R., Zaunders J., Brown D.A., Pankhurst S., Russell P.J., Breit S.N. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 2003, 63:5034-5040.
27. Mehar A., Macanas-Pirard P., Mizokami A., Takahashi Y., Kass G.E., Coley H.M. The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J. Pharmacol. Exp. Ther. 2008, 324:1181-1187.
28. John-Aryankalayil M., Palayoor S.T., Cerna D., Falduto M.T., Magnuson S.R., Coleman C.N. NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol. Cancer Ther. 2009, 8:261-273.
29. Zhan Q. Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat. Res. 2005, 569:133-143.
30. Li Y., Li X., Hussain M., Sarkar F.H. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004, 6:158-167.
31. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
32. Fan J., Ren H., Fei E., Jia N., Ying Z., Jiang P., Wu M., Wang G. Sumoylation is critical for DJ-1 to repress p53 transcriptional activity. FEBS Lett. 2008, 582:1151-1156.
33. Sauer L., Gitenay D., Vo C., Baron V.T. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 2010, 29:2628-2637.
34. Ma Y., Cheng Q., Ren Z., Xu L., Zhao Y., Sun J., Hu S., Xiao W. Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Lett. 2012, 317:150-156.
35. Abdulkadir S.A., Qu Z., Garabedian E., Song S.K., Peters T.J., Svaren J., Carbone J.M., Naughton C.K., Catalona W.J., Ackerman J.J., Gordon J.I., Humphrey P.A., Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat. Med. 2001, 7:101-107.
36. Levin W.J., Press M.F., Gaynor R.B., Sukhatme V.P., Boone T.C., Reissmann P.T., Figlin R.A., Holmes E.C., Souza L.M., Slamon D.J. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 1995, 11:1261-1269.
37. Virolle T., Krones-Herzig A., Baron V., De Gregorio G., Adamson E.D., Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J. Biol. Chem. 2003, 278:11802-11810.
38. Baron V., De Gregorio G., Krones-Herzig A., Virolle T., Calogero A., Urcis R., Mercola D. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 2003, 22:4194-4204.
39. Yang S.Z., Abdulkadir S.A. Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells. J. Biol. Chem. 2003, 278:39906-39911.
40. Yu J., de Belle I., Liang H., Adamson E.D. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Mol. Cell 2004, 15:83-94.
41. Nose K., Ohba M. Functional activation of the egr-1 (early growth response-1) gene by hydrogen peroxide. Biochem. J. 1996, 316(Pt 2):381-383.
42. Stuart J.R., Kawai H., Tsai K.K., Chuang E.Y., Yuan Z.M. C-Abl regulates early growth response protein (EGR1) in response to oxidative stress. Oncogene 2005, 24:8085-8092.
43. Pelzer A.E., Bektic J., Haag P., Berger A.P., Pycha A., Schafer G., Rogatsch H., Horninger W., Bartsch G., Klocker H. The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J. Urol. 2006, 175:1517-1522.
44. Huang X., Li X., Guo B. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J. Biol. Chem. 2008, 283:29795-29801.
45. Baek S.J., Kim J.S., Nixon J.B., DiAugustine R.P., Eling T.E. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J. Biol. Chem. 2004, 279:6883-6892.
46. Thyss R., Virolle V., Imbert V., Peyron J.F., Aberdam D., Virolle T. NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J. 2005, 24:128-137.
47. Ramachandran K., Gopisetty G., Gordian E., Navarro L., Hader C., Reis I.M., Schulz W.A., Singal R. Methylation-mediated repression of GADD45 alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009, 69:1527-1535.